Abstract
Coronavirus disease 2019 (COVID-19) outbreak, arisen in Wuhan, China. It is very series disease. Started with pneumonia of unknown etiology which have been reported to the World Health Organization (WHO) on 31 December 2019. Novel coronavirus (2019-nCov) was identified and isolated by Chinese health authorities on 7 January 2020, and it was sharing the same receptor, Angiotensin-converting enzyme 2 (ACE2) as SARS-CoV, ACE2 RNA expression profile in the normal human lung and ACE2 virus receptor expression is concentrated in a small population of type II alveolar cells. This study highlights important questions regarding the pathophysiology, and treatment options of COVID-2019; firstly, is the dry cough associated with the course of illness of COVID-2019 due to the overproduction of bradykinin? Secondly, is the ARDS and mortality associated with COVID-2019 are due to pneumonia or angioedema like illness?